Effects of intensity-modulated radiotherapy combined with capecitabine on peripheral blood CD4+/CD8+ in patients with advanced nasopharyngeal carcinoma(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2022年第8期
- Page:
- 946-949
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Effects of intensity-modulated radiotherapy combined with capecitabine on peripheral blood CD4+/CD8+ in patients with advanced nasopharyngeal carcinoma
- Author(s):
- ZHANG Faen
- Department of Oncology, Hechi Peoples Hospital, Hechi 547000, China
- Keywords:
- Keywords: nasopharyngeal carcinoma intensity-modulated radiotherapy capecitabine peripheral blood CD4+/CD8+
- PACS:
- R816.96
- DOI:
- DOI:10.3969/j.issn.1005-202X.2022.08.005
- Abstract:
- Abstract: Objective To explore the effects of the combination of intensity-modulated radiotherapy (IMRT) and capecitabine on peripheral blood CD4+/CD8+ in patients with advanced nasopharyngeal carcinoma (NPC). Methods According to the random number table, 90 patients with advanced NPC were divided into observation group (45 cases) and control group (45 cases). The patients in control group received IMRT alone, and those in observation group received IMRT combined with capecitabine for 6 weeks. The clinical efficacy, levels of peripheral blood CD4+/CD8+ before and after treatment were compared between two groups. The incidence of adverse reactions during treatment, survival, recurrence and metastasis in both groups were recorded. Results The response rate of treatment was significantly higher in observation group than control group (71.11% vs 53.33%, P<0.05). After treatment, the levels of peripheral blood CD4+ and CD4+/CD8+ in observation group were significantly higher than those in control group, while the level of peripheral blood CD8+ was significantly lower than that in control group (P<0.05). The total incidence of adverse reactions such as myelosuppression and leukopenia in observation group was lower than that in control group, but there was no significant difference (33.33% vs 27.78%, P>0.05). The 1-year local non-recurrence, distant non-metastasis and disease-free survival rates in observation group were all higher than those in control group (P<0.05). Conclusion IMRT combined with capecitabine can significantly improve clinical efficacy in patients with advanced NPC, and effectively improve the immune function.
Last Update: 2022-09-05